Instructions for Ribonuclease (proteolytic enzymes) 10 vials
Composition proteolytic enzymes
1 bottle contains:
Active ingredient: ribonuclease* - 10 mg
* - received from the pancreas of cattle
Pharmacotherapy group
proteolytic agent
Method of application and dose Ribonuclease
A fine aerosol is used for inhalation. For one procedure, 25 mg is recommended and diluted in 3 to 4 mL of 0.9% saline or 0.5% procaine.
When used intrapleurally, 25 to 50 mg in 5 to 10 mL of 0.9% saline or 0.2% procaine solution is recommended.
A laryngeal syringe or catheter, including a bronchoscope, may be used to administer an endobronchial solution containing 25 to 50 mg.
When treating parodontosis and gingivitis, it is recommended to use 1% solution of the drug in 0.5% solution of procaine. Application around the neck of the tooth and solution-impregnated swabs are applied to the gingival pockets. The procedure lasts 30 minutes and is performed daily for 10 days.
For topical use, the drug is recommended to pour 0.025-0.05 g of powder on the wound or ulcerative surface and apply tissues or swabs moistened with 0.9% saline solution for 2-10 days.
For sinusitis, 5 to 10 mg of a drug in 3 to 5 mL of 0.9% saline solution is injected into the maxillary (maxillary) sinus after puncture and irrigation. For otitis disease, 0.5 to 1.0 mL of 0.1% saline solution prepared with 0.9% saline solution is recommended. After administration, the sinus and tympanic cavity should be washed with 0.9% saline solution after 30 minutes.
The maximum single dose when given topically and intracavitously is 50 mg.
For IM administration, 5 to 10 mg of a drug in 1 mL of 0.9% saline or 0.5% procaine solution is recommended. The course of treatment is 2-10 injections, which are carried out 1-2 times a day.
To treat tick-borne encephalitis, it is given as a single dose of 25 to 30 mg IM 6 times a day every 4 hours. For children, 5 to 8 mg (1 to 3 years), 10 to 14 mg (4 to 6 years), 15 to 18 mg (7 to 11 years), 20 mg (12 to 15 years) are recommended depending on body weight. The drug is dissolved in 2 mL of 0.25% or 0.5% procaine before injection. Before treatment begins, drug susceptibility testing is done by injecting 0.1 mL of IV onto the flexor surface of the forearm. If there is no local or general reaction after an hour, the full dose may be given. The drug should be stopped after 2 days of return to normal temperature.
Testimony Ribonuclease
Respiratory tract disorders that produce viscous and difficult-to-remove sputum include conditions such as bronchiectasis, lung abscesses, pulmonary atelectasis, and exudative pleuritis. In addition, problems such as periodontosis, gingivitis, suppurative wounds, fistulas, abscesses, and trophic ulcers also require attention and treatment. Sinus disorders, such as acute and exacerbation of chronic sinusitis and deterioration of otitis media, including the perforated stage, are also considered serious disorders. It should also be noted that in severe tick-borne encephalitis associated with certain gamma globulin, appropriate measures should be taken to treat it.
Pharmacodynamics Ribonuclease proteolytic enzymes
The pharmacodynamics of said enzyme preparation consists in the ability thereof to depolymerize ribonucleic acid (RNA) to acid-soluble mono- and oligonucleotides. In addition, its action contributes to the liquefaction and elimination of pus, mucus, viscous and thick sputum. It also has anti-inflammatory effects. It is important to note that this drug destroys nucleic acids and slows the reproduction of a number of RNA viruses.
- ICD-10 proteolytic enzymes Code Indication
- A84 Tick-borne viral encephalitis
- H66 Suppurative and unspecified otitis media
- I80 Phlebitis and thrombophlebitis
- J01 Acute sinusitis
- J32 Chronic sinusitis
- J47 Bronchiectasis
- J85 Abscess of lung and mediastinum
- J86 Pyothorax (pleural empyema)
- J90 Pleural effusion
- J98.1 Pulmonary collapse (including atelectasis)
- K05 Gingivitis and periodontal diseases
- L02 Skin abscess, furuncle and carbuncle
- L98.4 Chronic skin ulcer, not elsewhere classified
- R09.3 Sputum
- T79.3 Posttraumatic wound infection, not elsewhere classified